Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pediatric nipocalimab study in generalized myasthenia gravis
NL-OMON59618Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of nipocalimab in myasthenia gravis (MG), sponsored by Janssen Pharmaceutical. Started Oct 2022; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON59618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59618.